EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ovoca Bio's Enterprise Value is €-3.85 Mil.
Ovoca Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.67 Mil. Therefore, Ovoca Bio's EV-to-FCF for today is 2.30.
The historical rank and industry rank for Ovoca Bio's EV-to-FCF or its related term are showing as below:
DUB:OVXA'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.2 Med: 0 Max: 4.29
Current: 2.3
During the past 13 years, the highest EV-to-FCF of Ovoca Bio was 4.29. The lowest was -1.20. And the median was 0.00.
DUB:OVXA's EV-to-FCF is ranked better than 59.08% of 369
companies
in the Biotechnology industry
Industry Median: 8.9
vs DUB:OVXA: 2.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-27), Ovoca Bio's stock price is €0.0065.
Ovoca Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.028. Therefore, Ovoca Bio's PE Ratio for today is At Loss.
Ovoca Bio EV-to-FCF Historical Data
The historical data trend for Ovoca Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ovoca Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovoca Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovoca Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ovoca Bio's EV-to-FCF falls into.
Ovoca Bio's current Enterprise Value is €-3.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ovoca Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovoca Bio (DUB:OVXA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ovoca Bio's share price for today is €0.0065.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ovoca Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ovoca Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Ovoca Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DUB:OVXA has been successfully added to your 